Muna Bhanji is the Founder and President of Tiba Global Access LLC, an independent senior advisory practice focused on commercialization and market access strategy development, serving the biopharmaceutical industry. Throughout her career, Muna has demonstrated an unwavering commitment to saving and improving lives, working with healthcare providers, patients, and payers to support access to breakthrough innovations.
Her prior experience includes a 34+ year tenure at Merck, during which she held a number of senior leadership roles within the US and Global commercial organizations driving growth across a broad portfolio of medicines and vaccines of over $40+ billion annually. Her strategic and operational experience includes SVP roles heading up Global Oncology, Global Hospital and Specialty Products and Global Market Access & Policy, with responsibility for enabling payer reimbursement and access for patients, for the company’s products worldwide.
In addition to corporate board service at Cytokinetics, Veracyte and Ardelyx, Muna serves on the board of Lumanity (portfolio company within Arsenal Capital Partners) as well as Chair of Lumanity’s Strategic Advisory Board. She is also a Director at Corus International, a humanitarian organization committed to poverty alleviation for those living in the most difficult circumstances. Prior board service includes the Boards of Possible Health, a Nepal based NGO, the Foundation of Managed Care Pharmacy as well as Chair, Merck’s Supervisory Board in the Netherlands.